ATE102047T1 - Pharmazeutische zusammensetzung enthaltend interferon fuer bukkale verabreichung. - Google Patents

Pharmazeutische zusammensetzung enthaltend interferon fuer bukkale verabreichung.

Info

Publication number
ATE102047T1
ATE102047T1 AT88901169T AT88901169T ATE102047T1 AT E102047 T1 ATE102047 T1 AT E102047T1 AT 88901169 T AT88901169 T AT 88901169T AT 88901169 T AT88901169 T AT 88901169T AT E102047 T1 ATE102047 T1 AT E102047T1
Authority
AT
Austria
Prior art keywords
interferon
pharmaceutical composition
composition containing
buccal administration
containing interferon
Prior art date
Application number
AT88901169T
Other languages
English (en)
Inventor
Joseph M Cummins
Original Assignee
Texas A & M Univ Sys
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25455330&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE102047(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Texas A & M Univ Sys filed Critical Texas A & M Univ Sys
Application granted granted Critical
Publication of ATE102047T1 publication Critical patent/ATE102047T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT88901169T 1986-11-06 1988-05-26 Pharmazeutische zusammensetzung enthaltend interferon fuer bukkale verabreichung. ATE102047T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US92783486A 1986-11-06 1986-11-06
PCT/US1987/002998 WO1988003411A1 (en) 1986-11-06 1987-11-06 Improved interferon therapy
EP88901169A EP0341258B1 (de) 1986-11-06 1988-05-26 Pharmazeutische Zusammensetzung enthaltend Interferon für bukkale Verabreichung

Publications (1)

Publication Number Publication Date
ATE102047T1 true ATE102047T1 (de) 1994-03-15

Family

ID=25455330

Family Applications (1)

Application Number Title Priority Date Filing Date
AT88901169T ATE102047T1 (de) 1986-11-06 1988-05-26 Pharmazeutische zusammensetzung enthaltend interferon fuer bukkale verabreichung.

Country Status (10)

Country Link
US (1) US5019382A (de)
EP (1) EP0341258B1 (de)
KR (1) KR960003377B1 (de)
AT (1) ATE102047T1 (de)
AU (1) AU2634592A (de)
DE (1) DE3789239T2 (de)
HK (1) HK24695A (de)
OA (1) OA09144A (de)
WO (1) WO1988003411A1 (de)
ZA (1) ZA878295B (de)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5017371A (en) * 1988-01-06 1991-05-21 Amarillo Cell Culture Company, Incorporated Method for reducing side effects of cancer therapy
US5906816A (en) * 1995-03-16 1999-05-25 University Of Florida Method for treatment of autoimmune diseases
US5705363A (en) 1989-03-02 1998-01-06 The Women's Research Institute Recombinant production of human interferon τ polypeptides and nucleic acids
US6372206B1 (en) * 1989-03-02 2002-04-16 University Of Florida Orally-administered interferon-TAU compositions and methods
US5298222A (en) * 1989-08-09 1994-03-29 Osteotech, Inc. Process for disinfecting musculoskeletal tissue and tissues prepared thereby
FR2654343B1 (fr) * 1989-11-10 1994-08-05 Roussel Uclaf Utilisation d'un polypeptide ayant l'activite de l'interferon gamma pour la preparation de compositions pharmaceutiques destinees au traitement de cancers primitifs de la plevre.
US5215741A (en) * 1990-10-30 1993-06-01 Amarillo Cell Culture Company, Incorporated Method for prevention of parasite infections
WO1992017209A1 (fr) * 1991-04-08 1992-10-15 Sumitomo Pharmaceuticals Company, Limited Preparation solide poreuse contenant une substance proteique physiologiquement active
AU669132B2 (en) * 1991-10-11 1996-05-30 Mark Cedric Gillies Treating ophthalmic fibrosis using interferon-alpha
WO1993006856A1 (en) * 1991-10-11 1993-04-15 Mark Cedric Gillies Treating ophthalmic fibrosis using interferon-alpha
US5863530A (en) * 1991-10-11 1999-01-26 Spruson & Ferguson Treating ophthalmic fibrosis using interferon-α
US5676942A (en) * 1992-02-10 1997-10-14 Interferon Sciences, Inc. Composition containing human alpha interferon species proteins and method for use thereof
DE69431320T2 (de) * 1993-04-09 2003-04-17 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo, Okayama Verwendung von menschlichem Interferon-d zur Herstellung eines Arzneimittels zur Behandlung von Atemwegserkrankungen in Katzen
US5885567A (en) * 1993-10-22 1999-03-23 University Of Connecticut Treatment of infection in fowl by oral administration of avian interferon proteins
US7790153B2 (en) * 1994-04-12 2010-09-07 Research Development Foundation Method of treating rheumatoid arthritis using orally administered type one interferons
IL113280A (en) * 1994-04-12 2004-12-15 Res Dev Foundation A preparation for the treatment of self-immunization diseases with the help of interferon of one type
US5939286A (en) * 1995-05-10 1999-08-17 University Of Florida Hybrid interferon tau/alpha polypeptides, their recombinant production, and methods using them
WO1997007820A1 (fr) * 1995-08-30 1997-03-06 Toray Industries, Inc. Remede destine aux maladies cardiaques
CA2236591C (en) 1995-11-02 2012-01-03 Schering Corporation Continuous low-dose cytokine infusion therapy
DK0886527T3 (da) * 1996-02-28 2002-03-04 Unihart Corp Farmaceutiske sammensætninger indeholdende naturligt humant alfa-interferon
US6509313B1 (en) 1996-02-28 2003-01-21 Cornell Research Foundation, Inc. Stimulation of immune response with low doses of cytokines
US6204022B1 (en) 1996-04-12 2001-03-20 Pepgen Corporation And University Of Florida Low-toxicity human interferon-alpha analogs
AU2520397A (en) * 1996-04-22 1997-11-12 Peter R. Rothschild Stabilized antihepatitis-b vaccine tablets
WO1997041885A1 (en) * 1996-05-09 1997-11-13 Feronpatent Limited Stabilization of interferons in aqueous solution for manufacture of sublingually administered tablets
CN1151840C (zh) * 1996-05-09 2004-06-02 太平洋制药控股公司 干扰素在制备用于治疗哺乳动物肿瘤病的药剂中的应用
AUPN976596A0 (en) * 1996-05-09 1996-05-30 Pharma Pacific Pty Ltd Stimulation of host defence mechanisms
US20030108519A1 (en) * 1996-05-09 2003-06-12 Pharma Pacific Pty Ltd. Therapeutic applications of high dose in terferon
AU724689B2 (en) 1996-05-09 2000-09-28 Pharma Pacific Pty Ltd Method of treatment
US6207145B1 (en) 1997-05-09 2001-03-27 Pharma Pacific Pty Ltd. Therapeutic applications of high dose interferon
JP2001526662A (ja) * 1997-05-09 2001-12-18 フェロンパテント リミテッド 舌下投与式タブレットの製造のための水溶液におけるインターフェロンの安定化
US6660258B1 (en) 1997-05-09 2003-12-09 Pharma Pacific Pty Ltd Oromucosal cytokine compositions and uses thereof
FR2769505B1 (fr) * 1997-10-10 2000-06-30 Michael Gerard Tovey Compositions de cytokines a administrer a la muqueuse buccale, et leurs utilisations
FI980216A0 (fi) * 1998-01-30 1998-01-30 Bene Pharma Oy Medicin foer behandling av vaorfor
CN1108815C (zh) * 1998-02-25 2003-05-21 上海华晨生物技术研究所 复方α干扰素含片及其制备方法
US6036949A (en) * 1998-03-05 2000-03-14 Amarillo Biosciences, Inc. Treatment of fibromyalgia with low doses of interferon
ATE300952T1 (de) * 1999-12-09 2005-08-15 Chiron Corp Verfahren zur verabreichung von wirkstoffen in das zentrale nervensystem oder lymphsystem
WO2001072312A1 (en) * 1999-12-22 2001-10-04 Viron Corporation Antiviral therapeutic composition and treatment
US7105154B2 (en) * 2000-07-19 2006-09-12 Pepgen Corporation Method of treatment using interferon-tau
US6746670B2 (en) * 2000-08-15 2004-06-08 Schering Corporation Regulatory T cells; methods
BR0115392A (pt) 2000-11-03 2004-06-15 Biomedicines Inc Método para o tratamento de uma doença sensìvel a interferona em um animal de sangue quente, método para individualizar as dosagens de uma interferona no tratamento, método para a fabricação de um dispositivo de liberação de efeito terapêutico de longa duração de uma droga ao longo de um perìodo de tempo, e conjunto útil para a ministração de uma quantidade relativamente constante de uma droga
CA2454860A1 (en) * 2001-08-12 2003-02-27 Pepgen Corporation Hybrid interferon/interferon tau proteins, compositions and methods of use
JP2005508935A (ja) * 2001-10-05 2005-04-07 インターミューン インコーポレイテッド 肝線維症およびｃ型肝炎ウイルス感染症を治療する方法
US20030143197A1 (en) * 2001-11-09 2003-07-31 Moran S. Mark Method for treating diseases with omega interferon
WO2003061728A2 (en) * 2002-01-16 2003-07-31 Pepgen Corporation Oral administration of interferon-tau
US7625554B2 (en) * 2002-09-05 2009-12-01 Brod Staley A Treatment of alzheimer's disease
DE60332358D1 (de) * 2002-09-09 2010-06-10 Hanall Pharmaceutical Co Ltd Protease-resistente modifizierte interferon alpha polypeptide
PL377612A1 (pl) * 2002-09-27 2006-02-06 Biogen Idec Ma Inc. Terapie przewlekłej zapalnej polineuropatii demielinizacyjnej z użyciem interferonu-ß
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
JP2005179268A (ja) * 2003-12-19 2005-07-07 Gc Corp 口腔用組成物
US8778880B2 (en) 2004-02-02 2014-07-15 Ambrx, Inc. Human growth hormone modified at position 35
WO2005120540A2 (en) * 2004-06-09 2005-12-22 Schering Aktiengesellschaft Interferon alpha or beta for treatment of cardiomyopathy and endothelial dysfunction
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
EP1985303B1 (de) 2006-01-12 2012-11-21 Kitasato Daiichi Sankyo Vaccine Co., Ltd. Alpha-Interferon enthaltende orale Zusammensetzung
US8075877B2 (en) * 2006-03-08 2011-12-13 Hemispherx Biopharma Broad spectrum immune and antiviral gene modulation by oral interferon
CN101437534A (zh) * 2006-03-08 2009-05-20 半球生物制药公司 口服干扰素的广谱免疫和抗病毒基因调节作用
WO2007140416A2 (en) 2006-05-30 2007-12-06 Intarcia Therapeutics, Inc. Two-piece, internal-channel osmotic delivery system flow modulator
PT2359808E (pt) 2006-08-09 2013-08-28 Intarcia Therapeutics Inc Sistemas de entrega osmótica e montagens de pistão
US20080260820A1 (en) * 2007-04-19 2008-10-23 Gilles Borrelly Oral dosage formulations of protease-resistant polypeptides
ES2402172T3 (es) 2007-04-23 2013-04-29 Intarcia Therapeutics, Inc Formulación en suspensión de péptidos insulinotrópicos y usos de los mismos
WO2009102467A2 (en) 2008-02-13 2009-08-20 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents
EP3735944A1 (de) 2009-09-28 2020-11-11 Intarcia Therapeutics, Inc. Schnelle initiierung und/oder beendigung der verabreichung substantiell stabiler arzneimittel
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
US8936782B2 (en) * 2011-11-22 2015-01-20 Cedars-Sinai Medical Center Interferon beta as antibacterial agents
US9642893B2 (en) 2013-07-03 2017-05-09 Joseph Cummins Method for reducing injury and stabilizing muscle using orally administered interferon
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
KR102650751B1 (ko) 2015-06-03 2024-03-22 인타르시아 세라퓨틱스 인코포레이티드 임플란트 배치 및 제거 시스템들
CN109310743A (zh) 2016-05-16 2019-02-05 因塔西亚制药公司 胰高血糖素受体选择性多肽及其使用方法
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
AU2018206539A1 (en) 2017-01-03 2019-07-18 Intarcia Therapeutics, Inc. Methods comprising continuous administration of a GLP-1 receptor agonist and co-administration of a drug
RU2690677C1 (ru) 2018-06-27 2019-06-05 Георгий Георгиевич Чумбуридзе Стабилизированная композиция, обладающая противовирусной, противоопухолевой, иммуномодулирующей, актопротекторной, антимутагенной и антиоксидантной активностью

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE180737C (de) *
US3536809A (en) * 1969-02-17 1970-10-27 Alza Corp Medication method
US3906092A (en) * 1971-11-26 1975-09-16 Merck & Co Inc Stimulation of antibody response
ZA754725B (en) * 1974-08-01 1976-06-30 H Stickl Preparation for the treatment of infectious diseases, method for the manufacture thereof, and its use
US3972995A (en) * 1975-04-14 1976-08-03 American Home Products Corporation Dosage form
DK485977A (da) * 1977-11-01 1979-05-02 Ess Foodeksport Fremgangsmaade til udvinding af et biologisk aktivt materiale fra svineblodfraktioner
GB2016015B (en) * 1978-01-22 1982-05-06 Hayashibara Co Method of preparing interferon and preparations containing interferon
GB2042888B (en) * 1979-03-05 1983-09-28 Teijin Ltd Preparation for administration to the mucosa of the oral or nasal cavity
US4713239A (en) * 1979-05-29 1987-12-15 Vsesojuny Kardiologichesky Nauchny Tsentr Adkaemii Meditsinski Nauk Sssr Antianginal film and method of treating ischemic heart disease
US4358376A (en) * 1979-10-29 1982-11-09 Terumo Corporation Apparatus for detoxifying body fluid
US4460574A (en) * 1980-06-16 1984-07-17 Yabrov Alexander A Prophylaxis or treatment of interferon-sensitive diseases
WO1982000588A1 (en) * 1980-08-22 1982-03-04 Illinois Univ Delivery of biologically active components of heterologous species interferon isolates
US4462985A (en) * 1980-08-22 1984-07-31 University Of Illinois Foundation Delivery of biologically active components of heterologous species interferon isolates
WO1983001198A1 (en) * 1981-10-08 1983-04-14 Kurt Frimann Berg Method and composition for treating a patient suffering from interferon-susceptible disorder
EP0080879B1 (de) * 1981-11-28 1986-10-01 Sunstar Kabushiki Kaisha Stabilisiertes Interferon enthaltende pharmazeutische Zusammensetzung
CA1208558A (en) * 1982-10-07 1986-07-29 Kazuo Kigasawa Soft buccal
DE3381553D1 (de) * 1982-10-25 1990-06-21 Genentech Inc Synergistische humaninterferonaktivitaet.
US4497795A (en) * 1982-12-13 1985-02-05 The Texas A&M University System Method of regulating appetite and efficiency of food utilization employing interferon
US4820515A (en) * 1982-12-13 1989-04-11 Texas A&M University System Method of using interferon in low dosage to regulate appetite and efficiency of food utilization
US4746508A (en) * 1983-06-06 1988-05-24 Beth Israel Hospital Assn. Drug administration
US4699136A (en) * 1983-12-22 1987-10-13 Krauser Robert S Method and apparatus for treating ailments
US4649075A (en) * 1984-08-09 1987-03-10 Leonora Jost Transdermal and transmucosal vortexed foam devices and the method of making
US4605555A (en) * 1984-09-20 1986-08-12 Sun Star Kabushiki Kaisha Composition and method for treating keratosic disorder of skin and mucosa
EP0177342A3 (de) * 1984-10-04 1987-12-02 Genentech, Inc. Orale Formulierungen therapeutischer Proteine
US4710191A (en) * 1985-12-16 1987-12-01 Jonergin, Inc. Therapeutic device for the administration of medicaments
US4828830A (en) * 1986-01-24 1989-05-09 Genentech, Inc. Method and composition for prophylaxis and treatment of viral infections
US4764378A (en) * 1986-02-10 1988-08-16 Zetachron, Inc. Buccal drug dosage form
US4803072A (en) * 1986-09-10 1989-02-07 Smithkline Beckman Corporation Immunomodulation

Also Published As

Publication number Publication date
DE3789239D1 (de) 1994-04-07
AU2634592A (en) 1992-12-03
EP0341258A4 (en) 1990-10-10
ZA878295B (en) 1988-05-03
EP0341258B1 (de) 1994-03-02
DE3789239T2 (de) 1994-06-16
AU1222788A (en) 1988-06-01
WO1988003411A1 (en) 1988-05-19
KR890700035A (ko) 1989-03-02
OA09144A (en) 1991-10-31
US5019382A (en) 1991-05-28
HK24695A (en) 1995-03-03
KR960003377B1 (ko) 1996-03-09
AU625431B2 (en) 1992-07-09
EP0341258A1 (de) 1989-11-15

Similar Documents

Publication Publication Date Title
ATE102047T1 (de) Pharmazeutische zusammensetzung enthaltend interferon fuer bukkale verabreichung.
DK0490944T3 (da) Transmucosal doseringsform
DE69003392D1 (de) Dosisform zur oralen verabreichung des hypoglykämischen glipizids.
DK0600079T3 (da) Oral 1alpha-hydroxyprævitamin D
NO920856D0 (no) Innretning for administrering av medikamenter for slimhinnevev
ATE204178T1 (de) Methode zur behandlung und vorbeugung von typ-1 diabetis durch orale verabreichung von insulin
ATE96308T1 (de) Dosierform fuer verabreichung in der humanmedizin.
UA37278C2 (uk) Протикашльова фармацевтична композиція для перорального введення
KR890004705A (ko) 항바이러스성 제제
OA08768A (fr) Traitement du virus su SIDA par l'interféron alpha humain recombinant.
ATE91890T1 (de) Herstellung eines arzneimittels gegen arthritis und rheumatismus.
ATE47664T1 (de) Pharmazeutische dosierungseinheit.
DE3689254D1 (de) Arzneimittel auf Dextrorphanbasis zur intranasalen Applikation.
DK374388A (da) Immunterapeutisk, oral interferondosisform samt fremgangsmaade til fremstilling heraf
Das et al. A brief review of muco-protective agent in the treatment of recurrent aphthous ulcer and behcet’s syndrome: Rebamipide
FR2507084B1 (fr) Composition antibiotique pour l'administration de la phosphomycine sous forme de comprimes a dissolution lente
DE3686536D1 (de) Oxytocin und antigestagen zur einleitung der geburt.
KR890001558A (ko) 공황(恐慌) 장애를 경감시키는 제피론 및 이의 약학적 허용 산부가염
PT1100476E (pt) Formulacoes para uma administracao transdermica de fenoldopam
MY102687A (en) Novel galenical comprising a somatostatin formulations.
IT1283945B1 (it) Uso dell'interferone alfa naturale umano da cellule linfoblastoidi per la terapia delle epatiti virali, neoplasie e sindromi da
IT1284852B1 (it) Uso dell'interferone alfa naturale umano da cellule leucocitarie per la terapia delle epatiti virali, neoplasie e sindromi da
HUP9902188A2 (hu) Természetes humán alfa-interferont tartalmazó gyógyszerkészítmények
AR003957A1 (es) Composicion farmaceutica para tratar un paciente mamifero que sufre una enfermedad vascular cronica progresiva (cpvd)

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee